tradingkey.logo

ADMA Biologics Inc

ADMA
查看详细走势图
16.430USD
+0.490+3.07%
收盘 02/06, 16:00美东报价延迟15分钟
3.92B总市值
18.51市盈率 TTM

ADMA Biologics Inc

16.430
+0.490+3.07%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.07%

5天

-5.03%

1月

-12.70%

6月

-1.91%

今年开始到现在

-9.92%

1年

-1.68%

查看详细走势图

TradingKey ADMA Biologics Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

ADMA Biologics Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在药品行业排名32/159位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价25.67。中期看,股价处于上升通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

ADMA Biologics Inc评分

相关信息

行业排名
32 / 159
全市场排名
95 / 4521
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
极度看好

ADMA Biologics Inc亮点

亮点风险
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
业绩高增长
公司营业收入稳步增长,连续3年增长176.77%
业绩转盈
公司业绩转盈,最新年度盈利美元
估值合理
公司最新PE估值18.51,处于3年历史合理位
机构加仓
最新机构持股228.97M股,环比增加0.04%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值3.19K

分析师目标

根据 3 位分析师
买入
评级
25.667
目标均价
+55.65%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

ADMA Biologics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

ADMA Biologics Inc简介

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
公司代码ADMA
公司ADMA Biologics Inc
CEOGrossman (Adam S)
网址https://www.admabiologics.com/
KeyAI